TL;DR
This study leverages plasma cell-free RNAs (cfRNAs) from both human and microbial sources to develop a more accurate method for detecting and classifying various cancer types. By integrating these dual sources, researchers achieved a significant improvement in cancer detection accuracy and the ability to pinpoint primary tumor locations, offering a promising avenue for non-invasive cancer diagnostics.
What Problem Does This Paper Address?
The early and accurate detection of cancer, along with the identification of its primary site, remains a critical challenge in clinical oncology. While liquid biopsies using cell-free DNA (cfDNA) have shown promise, the utility of cell-free RNA (cfRNA) in plasma for cancer diagnostics is still being explored. Furthermore, the role of microbial cfRNAs in plasma, which are often overlooked or treated as contaminants, has not been fully integrated into cancer detection strategies. This paper aims to bridge this gap by investigating the combined diagnostic power of human and microbial cfRNAs in plasma for detecting and classifying five major cancer types.
Methods
The researchers employed a SMART-based total RNA sequencing (SMART-total) method to profile plasma cfRNAs. This technique is optimized for low-input and potentially degraded RNA samples, making it suitable for plasma cfRNA analysis. A key aspect of their approach was the development of a comprehensive bioinformatic pipeline designed to meticulously filter out potential contaminations from laboratory reagents and the environment. This pipeline involved:
- Adapter trimming and quality control: Standard preprocessing steps to clean the sequencing data.
- Mapping to human and microbial genomes: Reads were aligned to the human genome, circular RNA back-spliced junctions, and microbial genomes (bacteria and viruses).
- K-mer and alignment-based classification: Two distinct methods were used for microbial identification to ensure robustness.
- Contamination filtering: Rigorous exclusion of reads from known laboratory contaminants, control samples, and common skin microbes.
- Differential analysis: Using edgeR to identify significantly altered gene and genus abundances between cancer patients and healthy donors, as well as cancer-type specific features.
- Machine learning for classification: Bootstrapping and balanced random forest classifiers were used to evaluate the performance of human and microbial cfRNA features for binary (cancer vs. healthy) and multiclass (cancer type) classification.
Datasets
The study utilized a cohort of approximately 300 plasma samples, including:
- Cancer Patients: Samples from 5 major cancer types: colorectal cancer, stomach cancer, liver cancer, lung cancer, and esophageal cancer. The majority of these patients were in early stages (I and II).
- Healthy Donors (HDs): Control samples from individuals without cancer.
The sequencing data generated in this study has been deposited in the Gene Expression Omnibus (GEO) under accession code GSE174302. A previously published dataset (GSE142987) was also used for validation.
Key Insights and Ideas
- Microbial cfRNAs are not just noise: The study strongly demonstrates that microbial cfRNAs in plasma are consistently detectable and, crucially, carry clinically relevant information for cancer detection, rather than being solely artifacts of contamination.
- Dual-source signatures are powerful: Combining human and microbial cfRNA profiles significantly enhances the accuracy of cancer detection and classification compared to using either source alone. This suggests a complex interplay between the host and its microbiome in the context of cancer.
- Immune suppression signals: Downregulated human gene pathways related to immune function and the increased prevalence of Torque Teno Viruses (TTVs) in cancer patients point towards a potential link between cancer and an immunosuppressed state.
- Cancer type specificity extends to microbes: Just as human cfRNAs show specificity for different cancer types, so do microbial cfRNAs, offering a novel layer of diagnostic information.
Key Results
- Cancer vs. Healthy Donor Classification: The combined human and microbial cfRNA profiles achieved an Area Under the Receiver Operating Characteristic Curve (AUROC) of approximately 0.9 for distinguishing cancer patients from healthy donors.
- Cancer Type Classification:
- Using human cfRNA features alone, the average recall for classifying the five cancer types was 52.5%.
- Using microbial cfRNA features alone (k-mer based), the average recall was 58.4%.
- Combining human and microbial features significantly improved the average recall to 60.4%, an 8% increase compared to human features alone.
- The average top 2 recall also improved from 7.9% (human alone) to 6.2% (combined).
- Identification of Specific Biomarkers: The study identified specific human genes (e.g., ADAM10, TMEM165) and microbial genera (e.g., Orthohepadnavirus, TTVs, Mycoplasma) associated with particular cancer types.
Limitations and Future Work
- Cohort Size and Diversity: While the study included ~300 samples, the authors acknowledge that a larger, more carefully designed cohort is necessary for clinical application. They also note potential imbalances in sex distribution for certain cancer types.
- Computational Mitigation: The researchers employed computational methods (RUVg) to mitigate batch effects and confounding factors, but acknowledge that these are complex issues in high-throughput data.
- Clinical Validation: The findings provide strong evidence for the clinical relevance and potential utility of cfRNAs, but further validation in larger, prospective clinical trials is essential before widespread clinical adoption.
- Understanding Microbial Roles: While microbial cfRNAs show diagnostic value, their precise biological roles in cancer development and progression require further investigation. The study highlights the potential for discovering understudied viruses.
Summary updated